InterveXion Therapeutics LLC
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Private
- Established
- 2004-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.intervexion.com
Multiple-Dose Study to Evaluate the Safety and Efficacy of IXT-m200
Phase 2
Terminated
- Conditions
- Methamphetamine-dependenceMethamphetamine Abuse
- Interventions
- Other: Placebo
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- InterveXion Therapeutics, LLC
- Target Recruit Count
- 61
- Registration Number
- NCT05034874
- Locations
- ๐บ๐ธ
Alpine Research, Clinton, Utah, United States
๐บ๐ธArtemis Institute for Clinical Research, San Diego, California, United States
๐บ๐ธWoodlands International Research Group, Little Rock, Arkansas, United States
Safety, Tolerability, and Pharmacokinetics of IXT-m200
- First Posted Date
- 2021-08-30
- Last Posted Date
- 2023-06-01
- Lead Sponsor
- InterveXion Therapeutics, LLC
- Target Recruit Count
- 9
- Registration Number
- NCT05027451
- Locations
- ๐บ๐ธ
Clinilabs Drug Development Corporation, Eatontown, New Jersey, United States
Meth-OD: A Study of IXT-m200 in Patients With Toxicity From Methamphetamine Overdose
Phase 2
Terminated
- Conditions
- Methamphetamine Intoxication (Disorder)
- Interventions
- First Posted Date
- 2021-01-20
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- InterveXion Therapeutics, LLC
- Target Recruit Count
- 20
- Registration Number
- NCT04715230
- Locations
- ๐บ๐ธ
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
๐บ๐ธSacred Heart Medical Center, Spokane, Washington, United States
๐บ๐ธUniversity of New Mexico Hospital, Albuquerque, New Mexico, United States
Study of Antibody for Methamphetamine Outpatient Therapy
Phase 1
Completed
- Conditions
- Methamphetamine-dependenceMethamphetamine Abuse
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-11-08
- Last Posted Date
- 2022-03-10
- Lead Sponsor
- InterveXion Therapeutics, LLC
- Target Recruit Count
- 77
- Registration Number
- NCT03336866
- Locations
- ๐บ๐ธ
Anaheim Clinical Trials, Anaheim, California, United States
๐บ๐ธPRA Health Sciences, Salt Lake City, Utah, United States
Safety Study of Ch-mAb7F9 for Methamphetamine Abuse
Phase 1
Completed
- Conditions
- Methamphetamine Abuse
- Interventions
- Biological: normal salineBiological: ch-mAb7f9
- First Posted Date
- 2012-05-22
- Last Posted Date
- 2014-05-13
- Lead Sponsor
- InterveXion Therapeutics, LLC
- Target Recruit Count
- 42
- Registration Number
- NCT01603147
- Locations
- ๐บ๐ธ
Quintiles Phase 1 Services, Overland Park, Kansas, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath